[go: up one dir, main page]

DK1773884T3 - Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor - Google Patents

Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor

Info

Publication number
DK1773884T3
DK1773884T3 DK05775603.3T DK05775603T DK1773884T3 DK 1773884 T3 DK1773884 T3 DK 1773884T3 DK 05775603 T DK05775603 T DK 05775603T DK 1773884 T3 DK1773884 T3 DK 1773884T3
Authority
DK
Denmark
Prior art keywords
targeting
therapeutic
compositions
similar
protein
Prior art date
Application number
DK05775603.3T
Other languages
English (en)
Inventor
Alessandro Moretta
Christina Bottino
Lorenzo Moretta
Roberta Castriconi
Original Assignee
Innate Pharma
Univ Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma, Univ Genova filed Critical Innate Pharma
Application granted granted Critical
Publication of DK1773884T3 publication Critical patent/DK1773884T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05775603.3T 2004-08-03 2005-08-02 Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor DK1773884T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59872704P 2004-08-03 2004-08-03
PCT/IB2005/002688 WO2006016276A2 (en) 2004-08-03 2005-08-02 Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor

Publications (1)

Publication Number Publication Date
DK1773884T3 true DK1773884T3 (da) 2012-05-21

Family

ID=35241619

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11186925T DK2412728T3 (da) 2004-08-03 2005-08-02 Terapeutiske præparater mod cancer, der er rettet mod 4Ig-B7-H3
DK05775603.3T DK1773884T3 (da) 2004-08-03 2005-08-02 Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11186925T DK2412728T3 (da) 2004-08-03 2005-08-02 Terapeutiske præparater mod cancer, der er rettet mod 4Ig-B7-H3

Country Status (9)

Country Link
US (3) US7732131B2 (da)
EP (2) EP2412728B1 (da)
JP (2) JP5130044B2 (da)
AT (1) ATE548389T1 (da)
AU (1) AU2005270918B2 (da)
CA (1) CA2575607C (da)
DK (2) DK2412728T3 (da)
ES (2) ES2381557T3 (da)
WO (1) WO2006016276A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20100203035A1 (en) * 2007-02-14 2010-08-12 Kwon Eugene D B7-h3 in cancer
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
US20110110940A1 (en) * 2008-04-15 2011-05-12 Oxigene, Inc. Methods for Enhancing the Efficacy of Vascular Disrupting Agents
FR2937470B1 (fr) 2008-10-16 2010-12-10 Fibercryst Systeme amplificateur optique pour laser impulsionnel a base d'un milieu a gain guidant et laser impulisionnel le comprenant
AU2010215838A1 (en) * 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-H3 antibody coupled bead assay for detection of circulating tumor cells
US9005616B2 (en) 2009-08-31 2015-04-14 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
JP2013509883A (ja) 2009-11-06 2013-03-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 臓器移植患者における移植片拒絶反応の非侵襲的診断方法
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2012004410A1 (en) * 2010-07-09 2012-01-12 Oslo Universitetssykehus Hf B7-h3 antagonists and taxanes
LT2703486T (lt) * 2011-04-25 2018-05-25 Daiichi Sankyo Company, Limited Anti-b7-h3 antikūnas
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
AU2015217278B2 (en) 2014-02-14 2020-03-19 Macrogenics, Inc. Improved methods for the treatment of vascularizing cancers
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
US10736963B2 (en) 2015-07-24 2020-08-11 Innate Pharma Methods for detecting tissue infiltrating NK cells
IL258521B2 (en) 2015-10-08 2024-01-01 Macrogenics Inc Combination therapy for the treatment of cancer
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
KR20190068602A (ko) 2016-10-21 2019-06-18 이나뜨 파르마 항-kir3dl2 작용제에 의한 치료
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
EP3558386A1 (de) 2016-12-21 2019-10-30 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
EP3880712A4 (en) 2018-11-16 2022-11-16 Albert Einstein College of Medicine MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
TW202124717A (zh) * 2019-12-30 2021-07-01 白素梅 人4IgB7-H3的突變編碼基因及其調節免疫的應用
JP2023529368A (ja) * 2020-06-03 2023-07-10 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Ｂ７ｈ３標的タンパク質及びその使用方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR401702A (fr) 1908-08-04 1909-09-13 Charles Marenghi Et Cie Soc Dispositif permettant d'imiter mécaniquement la mandoline
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
ATE159982T1 (de) 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
EP0954340B1 (en) 1996-05-03 2007-06-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
EA004790B1 (ru) 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения
US6090381A (en) 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
DK1490386T3 (da) 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
JPH11279009A (ja) 1998-03-26 1999-10-12 Sumitomo Chem Co Ltd 除草剤組成物
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU5812199A (en) 1998-09-08 2000-03-27 E.I. Du Pont De Nemours And Company Plant farnesyltransferases
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
AU4640600A (en) 1999-05-11 2000-11-21 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
ATE369384T1 (de) 1999-05-19 2007-08-15 Emd Lexigen Res Ct Corp Expression und export von interferon-alpha proteinen als fc fusionsproteine
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
JP4776845B2 (ja) 1999-11-15 2011-09-21 アンナート ファルマ エス．ア．エス． ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体
FR2804027B1 (fr) 2000-01-20 2002-08-30 Monoclonal Antibodies Therapeu Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
US6965018B2 (en) * 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002032375A2 (en) 2000-10-18 2002-04-25 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
US7740845B2 (en) * 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
JP2004528824A (ja) 2000-12-18 2004-09-24 アーンスティテュ ナシオナール ド ラ サント エ ド ラ ルシェルシェ メディカル（イー．エンヌ．エス．ウー．エール．エンム．） 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の新規な診断及び治療法
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US7736657B2 (en) 2002-02-10 2010-06-15 Apoxis S.A. Fusion constructs containing active sections on TNF ligands
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
EP1565489B1 (en) 2002-06-19 2010-11-17 Raven Biotechnologies, Inc. Internalizing antibodies specific for the RAAG10 cell surface target
PT1648507T (pt) 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk

Also Published As

Publication number Publication date
DK2412728T3 (da) 2015-04-07
US20130315892A1 (en) 2013-11-28
EP2412728A3 (en) 2012-05-02
AU2005270918B2 (en) 2011-03-03
AU2005270918A1 (en) 2006-02-16
WO2006016276A2 (en) 2006-02-16
JP5560301B2 (ja) 2014-07-23
JP2012197311A (ja) 2012-10-18
JP2008509130A (ja) 2008-03-27
ES2534288T3 (es) 2015-04-21
JP5130044B2 (ja) 2013-01-30
EP2412728B1 (en) 2015-01-07
US8465931B2 (en) 2013-06-18
WO2006016276A3 (en) 2006-05-04
US20100285531A1 (en) 2010-11-11
CA2575607C (en) 2017-07-11
ES2381557T3 (es) 2012-05-29
EP1773884A2 (en) 2007-04-18
US7732131B2 (en) 2010-06-08
CA2575607A1 (en) 2006-02-16
ATE548389T1 (de) 2012-03-15
US20080081346A1 (en) 2008-04-03
EP1773884B1 (en) 2012-03-07
EP2412728A2 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
DK1773884T3 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
MX2009004705A (es) Moleculas de enlace de albumina y usos de las mismas.
NO2019004I1 (no) patisiran: dekket gjennom sekvensene i kravene 1, 8 og 9 (se særlig krav 8 (b) og (c) i patentet. Det vises også til følgebrevet til søknaden.
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
WO2018026819A3 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
TW200740844A (en) Novel MAdCAM antibodies
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
WO2009015284A3 (en) Il-18 receptor antigen binding proteins
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
EA201001223A1 (ru) Стабилизированные белковые композиции
AU2013205271B2 (en) Human CGRP receptor binding proteins
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2005103081A3 (en) Human monoclonal antibodies against cd20
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
WO2009094148A3 (en) Ron antibodies and uses thereof
EA201070689A1 (ru) Композиция для личного ухода
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2011029008A3 (en) Synbodies to akt1